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Intensive research over the last decades has provided increasing evidence for neuroinﬂammation as an integral part in the
pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD). Inﬂammatory responses in the central nervous
system (CNS) are initiated by activated microglia, representing the ﬁrst line of the innate immune defence of the brain. Therefore,
biochemical markers of microglial activation may help us understand the underlying mechanisms of neuroinﬂammation in AD as
well as the double-sided qualities of microglia, namely, neuroprotection and neurotoxicity. In this paper we summarize candidate
biomarkers of microglial activation in AD along with a survey of recent neuroimaging techniques.
1.Introduction
1.1. Microglia in the Healthy Brain. The central nervous
system (CNS) has long been regarded as an immune privi-
leged organ, entirely separated from the peripheral immune
system. However, this concept has been fundamentally
revised in recent years, as more evidence about the existence
and the function of the innate immune defence of the brain
has become known [1]. Microglia play an outstanding role
in this context as these cells constitute the ﬁrst line of
defenceagainstnoxiousagentsinthebrain.Theyderivefrom
peripheral macrophages and display a ramiﬁed morphology
in the resting state. It is believed that their function is to
constantly scan the surrounding microenvironment in order
to detect possible changes in the extracellular homeostasis
of the brain that might be harmful to neurones. Upon
activation, microglia proliferate migrate to the site of
the lesion and undergo a drastic change in morphology,
obtainingphagocyticabilitiesandreleasingproinﬂammatory
cytokines. The main purpose of this process is to remove
cellular debris and ﬁnally to restore homeostasis in the
extracellular microenvironment of the brain, thus protecting
neuronal tissue from collateral damage [2].
1.2. Microglial Activation in Alzheimer’s Disease—Protective
or Destructive? . Over the last decades, increasing evidence
has suggested that neuroinﬂammation represents a crucial
part in the pathogenesis of AD as well as in other neu-
rodegenerative diseases [3]. It has been shown that activated
microglia can be found in AD brains, surrounding extracel-
lular deposits of β-amyloid, maintaining an inﬂammatory
milieu by secreting pro-inﬂammatory cytokines [4, 5]. It
has been hypothesized that this chronic inﬂammatory state
contributes decisively to the progression of the disease,
thus suggesting that activated microglia not only exert
neuroprotective eﬀects, but might also be detrimental for
the survival of neuronal tissue. It is still unknown why
and when, in the course of AD, microglia switch from
being beneﬁcial to becoming neurotoxic, but age-related
disturbance of the physiological function and regulation of
microglia (immunosenescence) has been suggested to play
an important role in the AD pathogenesis [6]. Another
question that remains to be answered is whether microglial
activationoccursasaconsequenceofextracellularβ-amyloid
deposition in AD, or if it serves as a triggering factor for
β-amyloid deposition in the initial stages of the disease.
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be activated by extracellular β-amyloid [7]. However, the
presence of activated microglia has been observed even
before the onset of β-amyloid deposition [8].
2.BiochemicalMarkers
2.1. Use of Biochemical Markers of Microglial Activation. Bio-
chemical markers of microglial activation that allow moni-
toring of the inﬂammatory state of the CNS, might be useful
for the comprehension of the double-edged characteristics of
microglia in AD. Furthermore, by investigating the relation
betweenbiomarkerlevelsanddiseaseprogression,theycould
contribute to the understanding of underlying pathogenic
mechanisms. In addition, comparing biochemical microglial
markers with neuroimaging markers will help visualize the
distribution of activated microglia throughout the brain.
Taking a long view, these biomarkers could also be used to
monitor therapy in studies of drugs that target microglial
activation.
Cerebrospinal ﬂuid (CSF) is in direct contact with the
brain parenchyma and pathological processes in the CNS
often lead to altered CSF levels of speciﬁc analytes, which is
the basis for using CSF biomarkers in research and clinical
neurology. During the last two decades, it has become clear
that several core neuropathological hallmarks of AD may
be monitored in CSF, with low Aβ42 levels secondary to
amyloid pathology, and high tau and phospho-tau levels,
secondary to axonal degeneration and tangle pathology,
respectively [9]. CSF is also a possible source for markers
of AD-related microglial activity. A number of biochemical
markers of microglial activation have been described and
investigated, not only in AD, but also in other diseases which
involve neuroinﬂammation and/or activation of peripheral
cells belonging to the macrophage lineage.
2.2. Chitotriosidase. Chitotriosidase is an enzyme that exerts
chitinolytic activity without having any known physiological
function in humans, as inherited enzyme deﬁciency remains
asymptomatic [10]. It appears as a product of activated
mononuclear cells and functions as a marker for lipid-laden
macrophages in peripheral blood, which can be used for
diagnosing and therapeutic monitoring of lysosomal storage
disorders such as Gaucher’s disease [11]. Chitotriosidase
activity in the CSF of AD patients is signiﬁcantly higher
than in cognitively healthy controls, which strengthens the
hypothesis that disease-related microglia markers may be
monitored in AD. However, CSF chitotriosidase activity
appears to be unsuitable as a diagnostic tool on its own, due
to large overlap between patients and controls [12].
2.3. CCL18. CCL18, also known as PARC (pulmonary ac-
tivation-regulated chemokine), is a macrophage-derived
chemokine that mainly attracts T-cells [13] and, precisely as
chitotriosidase, shows considerably elevated levels in blood
from patients with Gaucher’s disease, hence serving as a
suitable surrogate marker for lipid-laden macrophages in
lysosomal storage disorders [14]. The presence of CCL18 in
the CSF was demonstrated in patients suﬀering from infec-
tious meningitis [15]. Furthermore, the expression of CCL18
in the CNS has been elucidated in relation to traumatic
brain injury and cerebral tumours [16]a sw e l la st om y e l i n -
laden macrophages in and around demyelinating lesions
in multiple sclerosis [17], suggesting an anti-inﬂammatory
nature. In the previously mentioned study, CCL18 was not
detected in the CSF of AD patients [12].
2.4. YKL-40. YKL-40 is a member of the same protein
family as chitotriosidase (family 18 glycosyl hydrolases) and
is highly similar in structure to chitotriosidase, but lacks
chitinolytic activity as a result of a critical amino acid
substitution. Its biological function is widely unknown, but
a role in inﬂammation and tissue remodelling has been
suggested [18]. It is released by activated macrophages and
elevated concentrations have been measured in the CSF
of AD patients [19]. However, the diﬀerence in YKL-40
between patients and controls in the study cited above
was relatively small, with a large overlap between groups,
and an independent smaller study could not reproduce the
group diﬀerence [12], suggesting that alterations of CSF
YKL-40 in AD are too small for this biomarker to be of
diagnostic usability. However, more studies are needed to
determine the ultimate value of YKL-40 as a biomarker for
AD.
2.5. CCL2. CCL2, also known as MCP-1 (monocyte che-
moattractant protein 1), is a chemokine, measurable in CSF
and represents a microglial secretion factor that appears to
play an important role in macrophage migration [20]. Ele-
vated levels of CCL2 in the CSF of AD patients have been
described [21, 22], but a recent study failed to reproduce this
[12].
2.6. CD14. CD14 is a surface protein, mainly expressed by
macrophages and acts as a cofactor for toll-like receptors
(TLRs), which are essential for the recognition of pathogens
by the innate immune system of the brain [23]. In AD, it has
been shown that microglial TLRs and CD14 are involved in
the inﬂammatory reaction surrounding β-amyloid deposits
[24]. In animal models, the deletion of CD14 resulted
in a change of the inﬂammatory response, decreasing the
number of activated microglia and the amount of β-
amyloid plaques [25]. One study examined cell adhesion
molecules in puriﬁed monocytes from the peripheral blood
of patients with AD and cognitively normal controls and
found decreased ratios of monocytic ICAM-3/CD14 and
P-selectin/CD14 in AD [26]. These results suggest that
the expression of monocytic cell adhesion molecules is
decreased in AD. Another interpretation is that CD14
expression per se is increased. In fact, elevated levels of
a soluble form of CD14 were recently seen in CSF from
AD and Parkinson’s disease (PD) patients compared with
healthy controls [27]. The lack of longitudinal data in these
studies prevents from drawing any conclusion on whether
upregulation of CD14 is beneﬁcial or detrimental in the
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2.7. Neopterin. Neopterin is a degradation product deriving
from the purine nucleotide guanosine triphosphate (GTP).
It is secreted by macrophages upon activation and may
stimulate the production of reactive oxygen species (ROS)
[28, 29]. It can be utilized as an indicator for immune system
activation, showing elevated levels in several infectious
diseases, autoimmune disorders, and malignant tumours as
well as following allograft rejection [30]. Neopterin has even
been measured in the CSF of AD patients, however without
signiﬁcant diﬀerences compared to controls [31].
3. Neuroimaging
In vivo visualization of microglial activation has become
possible with the development and introduction of molec-
ular imaging ligands (tracers) for use with positron emission
tomography (PET) or single-photon emission tomography
(SPECT). Most so far available imaging ligands make use of
their high aﬃnity to the peripheral benzodiazepine binding
site (PBBS/PBR), also called translocator protein (TSPO), a
receptor located in the outer membrane of mitochondria.
Its upregulation within the CNS has been shown to reﬂect
neuroinﬂammatory processes, mainly due to the activation
of microglia [32, 33]. The most extensively employed PET
imagingligandtostudymicroglialactivationinvariousbrain
diseases both in humans and transgenic animal models is the
11C-labeled isoquinoline (R)-PK11195 (1-[2-chlorophenyl]-
N-methyl-N-[1-methyl- propyl]-3-isoquinoline carboxam-
ide) (PK11195), a speciﬁc ligand for the PBBS. An early
PK11195PETstudythatdidnotshowanydiﬀerencebetween
AD patients and a group of controls suﬀered from several
methodological issues [34]. Subsequent PET studies used
the aforementioned more active R-enantiomer of PK11195
and applied diﬀerent and more advanced quantiﬁcation
approaches to enhance tracer evaluation [35, 36].
One PK11195 PET study found increased binding levels
in the entorhinal, temporoparietal, and cingulate cortex in
a group of AD patients and one subject with mild cognitive
impairment (MCI) as compared to normal individuals [37].
Several studies have combined PK11195 PET imaging with
PET examinations using the ﬁbrillar amyloid imaging ligand
11C-Pittsburgh Compound B (PIB) and dementia assess-
ments to explore the relationship of microglial activation
with underlying pathology in AD and MCI. One of these
studies showed increased PK11195 binding in AD patients
in comparison with normal controls in parietotemporal
regions and a negative correlation with PIB retention levels
in the posterior cingulate, a region that also showed lowest
glucose metabolism as measured by 18F-FDG PET [38].
Another study found increased PK11195 binding in frontal,
temporal, parietal, occipital, and cingulate cortices and a
twofold elevated PIB retention in the same cortical areas of
ADsubjectswhencomparedtohealthycontrols[39].Astudy
in 14 MCI patients showed that half of them had increased
cortical PIB retention while ﬁve had increased PK11195
levels, and no regional correlation between the tracers was
found [40]. No diﬀerence in PK11195 binding between
mild and moderate AD patients, MCI patients and control
subjects and no regional correlation with PIB retention
were found once another study claiming that microglial
activation might be associated with later stages of AD alone
or that PK11195 might be too insensitive to detect microglial
activation at the examined disease stages [41]. This is in
disagreement with a study showing increases in microglial
activation even during healthy aging [42].
Even if PK11195 is still considered the “gold standard”,
the results of PET studies in AD and MCI have been
rather discordant, especially in earlier disease stages. New
tracers such as N-(2,5 dimethoxybenzyl)-N-(4-ﬂuoro-2-
phenoxyphenyl) acetamide (DAA1106) have higher binding
aﬃnity to PBBS and binding characteristics superior to
PK11195. One study has so far been conducted in AD
showing signiﬁcantly higher binding in prefrontal, temporal,
parietal, occipital, and cingulate cortices, as well as in
striatum and cerebellum of AD patients compared with
controls [43]. Another PBBS ligand, 11C-vinpocetine, has
been suggested as potential marker for microgliosis. No
diﬀerence between AD patients and age-matched control
subjects was observed, however, disease and age-speciﬁc
changes could successfully be displayed [44].
4. Conclusions
4.1.ClinicalApplicabilityofMicroglialActivationMarkers. As
microglia play a crucial role in the inﬂammatory response in
AD brains, the question arises whether measuring microglial
activity in the CSF or brain of AD patients might be useful
in clinical routine. In order to serve as a diagnostic tool
in AD investigations, these putative microglial biomarkers
must be capable of distinguishing between AD patients
and healthy individuals as well as from patients suﬀering
from other types of dementia. However, current research
suggests that microglial activation markers generally fail to
provide high enough diagnostic accuracy to be clinically
useful as diagnostic tools on their own. For comparison,
the established AD CSF biomarker triad (Aβ42, total-
tau and phospho-tau) has very high diagnostic accuracy
when evaluated in well-controlled settings, both in cross-
sectional studies [45] and in longitudinal studies of early
stage patients [46]. Thus, at present, microglial markers are
unlikely to add diagnostic performance to the available AD
investigation toolbox, although it cannot be excluded that
they might be more useful at certain well-deﬁned disease
stages [47]. Nonetheless, biomarkers of microglial activation
may give clues on underlying pathogenic mechanisms in AD
directly in vivo in human patients, particularly concerning
the ambivalence between neuroprotection and neurotoxicity
following microglial activation. In addition, as microglial
activation may aﬀect the progression rate in AD, biomarkers
could be useful for monitoring of the course of the disease
early on.
4.2. Further Research on Microglial Activation Markers.
Future eﬀorts investigating microglial activation markers
may focus on longitudinal studies trying to elucidate
whether high levels of microglial activation are beneﬁcial
or detrimental in relation to disease progression. Another4 International Journal of Alzheimer’s Disease
possible aspect is to ascertain the relation between microglial
biomarkers and neuroimaging markers which allow visualiz-
ing microglia in the living brain.
4.3. Possible Use of Microglial Activation Markers in Future
Studies. As microglia could become a target for possible
future therapies in AD [48], microglial activation markers
may even serve as a measuring tool for evaluating and
monitoring the eﬃciency of these therapeutic interventions.
Microglial markers may also be useful to identify subgroups
of patients with pronounced alteration of microglial activa-
tion, which might be most likely to respond to microglia
targeting treatment.
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